Imatinib (STI571)

Catalog No.S2475 Synonyms: CGP057148B, ST-1571

Imatinib (STI571) Chemical Structure

Molecular Weight(MW): 493.6

Imatinib (STI571) is a multi-target inhibitor of tyrosine kinase with inhibition for v-Abl, c-Kit and PDGFR, IC50 values are 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, respectively.

Size Price Stock Quantity  
USD 70 In stock
USD 120 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 35 Publications

6 Customer Reviews

  • Ba/F3-p210T315I cells were treated with indicated concentrations of imatinib with or without PDMP for 24 h. Apoptosis was determined as in A. Data are shown as percentage of sub-G1 for apoptosis in triplicate cultures. *P<0.05.

    FASEB J 2011 25, 3661-3673. Imatinib (STI571) purchased from Selleck.

    Targeting KITLG through c-KIT inhibition using Imatinib; one representative experiment is shown (n = 4).

    Oncotarget, 2016, 7(34):54583-54595. Imatinib (STI571) purchased from Selleck.

  •  

    Inhibition of thymidine (a and b) and cytarabine (c and d) uptake with imatinib. K562 cells (a and c) and MEG-01 cells (b and d) were incubated at 37 ◦C for 15 min with imatinib transport buffer, and then incubated with 0.5 Ci of [3H] thymidine or [3H] cytarabine for an additional 5 min in presence of imatinib. Cells were then washed 3 times, lysed and radioactivity associated to cell pellets was quantified. DMSO, dimethylsulfoxide; DPD, dipyridamole.

    Leukemia Res 2012 36, 1311-1314. Imatinib (STI571) purchased from Selleck.

    ZFX regulates imatinib sensitivity and PI3K/Akt signaling pathway in CML cells. Viability of cells transfected with si-ZFX at the indicated doses of imatinib for 24 h (a). Colonies of leukemia cells and imatinib-resistant cells transfected with si-ZFX following treatment with imatinib for 10 days (b). Western blot analysis of Akt, p-Akt, CyclinD1, CyclinE1, Bcl-2, and Caspase-3 in K562 and K562/G01 cells transfected with si-ZFX for 2 days (c). The relative densities of proteins were quantified and normalized to b-Actin (d). Values represented the mean ± SD data from experiments in triplicate. *P\0.05 and **P\0.01

    Cell Biochem Biophys, 2016, 74(2):277-83. Imatinib (STI571) purchased from Selleck.

  • Cell Viability assay results. A2C12, BetaD5, GammaA3, GammaD12, A549, CaCo2, HepG2 cell lines were treated with imatinib mesylate for 24h and 96h.

    Dr. Thomas Kruwel of Fraunhofer. Imatinib (STI571) purchased from Selleck.

    A. Viability curve for the c-Kit mutant MelMS melanoma cell line treated with increasing concentrations of imatinib for 72h (relative to DMSO-treated controls; mean ±sd; n=3) B. MelMS melanoma cells were treated with 50nM imatinib for 24h. The effects on c-Kit, ERK and AKT activation were determined by immunoblotting.

    Dr. Helen Rizos from the university of Sydney. Imatinib (STI571) purchased from Selleck.

Purity & Quality Control

Choose Selective PDGFR Inhibitors

Biological Activity

Description Imatinib (STI571) is a multi-target inhibitor of tyrosine kinase with inhibition for v-Abl, c-Kit and PDGFR, IC50 values are 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, respectively.
Targets
PDGFR [1]
(Cell-free assay)
c-Kit [2]
(M-07e cells)
v-Abl [1]
(Cell-free assay)
100 nM 100 nM 600 nM
In vitro

In vitro assays for inhibition of a panel of tyrosine and serine/threonine protein kinases show that Imatinib inhibits the v-Abl tyrosine kinase and PDGFR potently with an IC50 of 0.6 and 0.1 μM, respectively. [1] Imatinib inhibits the SLF-dependent activation of wild-type c-kit kinase activity with a IC50 for these effects of approximately 0.1 μM, which is similar to the concentration required for inhibition of PDGFR. [2] Imatinib exhibits growth-inhibitory activity on the human bronchial carcinoid cell line NCI-H727 and the human pancreatic carcinoid cell line BON-1 with an IC50 of 32.4 and 32.8 μM, respectively. [3] A recent study shows that Imatinib has the potential to exert its antileukemia effects in chronic myelogenous leukemia by down-regulating hERG1 K(+) channels, which are highly expressed in leukemia cells and appear of exceptional importance in favoring leukemogenesis. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LAMA-84 M1O2Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHyVItnUUN3ME2wMlA4OzB2IN88US=> NXPrOXNWW0GQR1XS
EM-2 M{j1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTBwMEi4PEDPxE1? MYjTRW5ITVJ?
MEG-01 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjPU4RPUUN3ME2wMlA5QTJzIN88US=> NVTveplVW0GQR1XS
BV-173 NWOwXVd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\iSWlEPTB;MD6xPFc1KM7:TR?= NVjXSpVoW0GQR1XS
K-562 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnH2TWM2OD1yLkKyOFMzKM7:TR?= M4nDbXNCVkeHUh?=
CGTH-W-1 NGTmXlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTMTWM2OD1yLkO4N|c1KM7:TR?= MYPTRW5ITVJ?
ST486 NHLzUoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGr1UpRKSzVyPUCuOlg2PCEQvF2= M{n4THNCVkeHUh?=
NCI-H1436 M4XEN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXZTWM2OD1yLkm3PFAyKM7:TR?= M2nGVXNCVkeHUh?=
NOS-1 Mlz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzuTWM2OD1zLk[1N|g{KM7:TR?= M4PF[nNCVkeHUh?=
A498 M4j4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYr5Z|VkUUN3ME2yMlU4OjJ|IN88US=> NGTMXo5USU6JRWK=
BE-13 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTJwNkKxNFYh|ryP NHHWOJdUSU6JRWK=
SUP-T1 NWDuN|JZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETvc5VKSzVyPUOuPFI6ODdizszN M2Dvd3NCVkeHUh?=
NCI-H1770 M{G0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjwTWM2OD13LkW3NlYzKM7:TR?= MVfTRW5ITVJ?
IMR-5 M4S2Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTZwMkKxOFch|ryP MVLTRW5ITVJ?
LB2241-RCC NYjnbYtUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmKwTWM2OD16LkC3N|g1KM7:TR?= MV3TRW5ITVJ?
TGBC24TKB MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLJTWM2OD16LkO0NFUzKM7:TR?= NELiNJVUSU6JRWK=
SCC-15 M1fNW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;FcZJNUUN3ME2xNE44Pzh6IN88US=> M{fhRXNCVkeHUh?=
BB49-HNC M3HTR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2[yemlEPTB;MUSuN|M{PSEQvF2= NV[y[FVxW0GQR1XS
ES7 NIPBT2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGe2eYtKSzVyPUG0Mlc{PzlizszN M1:yR3NCVkeHUh?=
LB2518-MEL Mn71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTF4Lk[wPVQh|ryP MoXKV2FPT0WU
NCI-H510A MnXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17nb2lEPTB;MUeuNlQ1OiEQvF2= MlzqV2FPT0WU
TE-441-T MnjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DRUmlEPTB;MUeuNlg5PiEQvF2= NVXwcmRLW0GQR1XS
HH MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTF5LkO5PVkh|ryP Mnv0V2FPT0WU
LC4-1 NE\Uem5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3NTWM2OD1zOD6wOlUzKM7:TR?= M3zIdnNCVkeHUh?=
KARPAS-45 MoXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvjTWM2OD1zOD6xPFQ5KM7:TR?= NWWxTHRPW0GQR1XS
LB1047-RCC NW\DfY5YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTF6LkS0OVIh|ryP MXzTRW5ITVJ?
NKM-1 MmKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\lTWM2OD1zOT6zOVUzKM7:TR?= MYfTRW5ITVJ?
SCLC-21H NGHZZWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTJyLkGyOFYh|ryP MWXTRW5ITVJ?
RS4-11 NXH6PG86T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXNTWM2OD1{MD6zN|A5KM7:TR?= MVjTRW5ITVJ?
ALL-PO NIHJdXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPH[Y9qUUN3ME2yNE45OTR7IN88US=> NXq3XmE1W0GQR1XS
GDM-1 M{PqU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XldWlEPTB;MkKuOVk1PSEQvF2= Mk\TV2FPT0WU
DMS-79 NYnpeJJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXi4d3RvUUN3ME2yOE41QTN2IN88US=> NXrSO5RNW0GQR1XS
MPP-89 NFr2d4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTJ3Lk[4O|Qh|ryP MWrTRW5ITVJ?
NB10 NY[xPHFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPRXnlZUUN3ME2yOk41Pjl7IN88US=> MYPTRW5ITVJ?
LS-513 MlrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\VZWlEPTB;Mk[uPFg1PyEQvF2= MnLRV2FPT0WU
L-540 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTJ4LkmxOFMh|ryP NXnlcpV4W0GQR1XS
ES1 NF\Rb3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TRNGlEPTB;MkeuOVIyKM7:TR?= MX;TRW5ITVJ?
NTERA-S-cl-D1 MoLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnyTWM2OD1|MD61NFk{KM7:TR?= MYTTRW5ITVJ?
EW-1 NFi3SpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXid4NDUUN3ME2zNk46PDV2IN88US=> MVXTRW5ITVJ?
Calu-6 NHWxbFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTN|LkG4OVUh|ryP M4DhU3NCVkeHUh?=
CTV-1 NHHMNIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjuVmlXUUN3ME2zN{46Pzh7IN88US=> MX\TRW5ITVJ?
YT NGX1eJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\LOGlEPTB;M{iuOVIxQSEQvF2= Ml3tV2FPT0WU
TE-6 NFWwTGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHNUJpKSzVyPUSxMlI4QThizszN NXjabmRSW0GQR1XS
HT-144 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjtWYdCUUN3ME20NU42PDh4IN88US=> MVjTRW5ITVJ?
EW-13 M2XifGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLHTWM2OD12Mj6yO|kyKM7:TR?= NEToUJBUSU6JRWK=
KALS-1 M3;PUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXMTWM2OD12Mz6xN|I6KM7:TR?= MoD1V2FPT0WU
MOLT-16 NVHQUGlMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlq5TWM2OD12NT6wO|UzKM7:TR?= NGD0e5RUSU6JRWK=
D-336MG MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPuWGJKSzVyPUS1Mlk2QTlizszN MlfBV2FPT0WU
TE-11 NUHyNXpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\1W3ZKSzVyPUS2MlY2OyEQvF2= NEf5fJdUSU6JRWK=
EB2 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;vSmlEPTB;NE[uOlk6KM7:TR?= MYfTRW5ITVJ?
SK-N-DZ MmDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vJXGlEPTB;NEiuNFk3OSEQvF2= M13L[3NCVkeHUh?=
SW684 NXfJToVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zF[WlEPTB;NEiuNlY6PSEQvF2= M4j0dXNCVkeHUh?=
EW-18 MmXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1z3SGlEPTB;NEiuOFM6PSEQvF2= NH7ZXlNUSU6JRWK=
RL95-2 Mm\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1H1TGlEPTB;NUCuNFcyKM7:TR?= NGDofphUSU6JRWK=
CHP-126 M4D1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTVyLki5NFUh|ryP MXLTRW5ITVJ?
NCI-H1395 NXLNUY8xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTVzLke4N|Uh|ryP NHOycpdUSU6JRWK=
TE-15 NHP2V3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTV{LkK1OVYh|ryP NUfJfpZEW0GQR1XS
ES4 NGK4e41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYj1UYJPUUN3ME21Nk46Pzd3IN88US=> NH;VeJhUSU6JRWK=
TE-1 M3;KfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTV|Lkm0OVUh|ryP MYjTRW5ITVJ?
SIMA MoX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTV5LkOzNVEh|ryP M4nBTHNCVkeHUh?=
LB647-SCLC NXXCcY9FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;ZTWM2OD14ND6xNVg5KM7:TR?= NIG0eVlUSU6JRWK=
KY821 NGnFSVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDqVGFKSzVyPU[0MlI2PTJizszN M3vkTHNCVkeHUh?=
LC-2-ad NXjmUnVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1y1VmlEPTB;NkWuO|YxOSEQvF2= M{LoSXNCVkeHUh?=
KP-N-RT-BM-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTZ4Lk[zOlYh|ryP M{S1TXNCVkeHUh?=
SW872 NGGzcIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHjTWM2OD14Nz60N|gzKM7:TR?= M365SXNCVkeHUh?=
ES5 NHe1fZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rjbWlEPTB;NkeuOlk3QCEQvF2= NHuxZXJUSU6JRWK=
SK-NEP-1 NVW3WoRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTZ6LkO4NFMh|ryP NXfxdI5XW0GQR1XS
RPMI-6666 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPIUJl2UUN3ME23NU4xOzJizszN MUDTRW5ITVJ?
UACC-812 MoXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDySJVEUUN3ME23NU4yPjB7IN88US=> NFrYOmhUSU6JRWK=
COLO-829 Ml3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NES2d3ZKSzVyPUeyMlY6QDdizszN MULTRW5ITVJ?
KP-N-YS NUXQcoNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLG[ZF7UUN3ME23Nk44OTN7IN88US=> NX[3eZB5W0GQR1XS
GI-1 NUDiNmd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETE[lJKSzVyPUezMlI5PjhizszN M2\pXXNCVkeHUh?=
ETK-1 NWPy[ZdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTd|LkS5N|Ih|ryP NVizRXZyW0GQR1XS
LXF-289 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3W1cGlEPTB;N{OuO|I6KM7:TR?= Mnf6V2FPT0WU
CAS-1 M4\wbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PFdmlEPTB;N{OuPFg2PyEQvF2= MnnuV2FPT0WU
EW-22 M3LEcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTd2LkexNVUh|ryP MlLzV2FPT0WU
NCI-H2196 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjrN5hKSzVyPUe1MlY{PzlizszN NF\lfnZUSU6JRWK=
EoL-1-cell NGTrN4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvSWIdKSzVyPUixMlY6PjNizszN NXfyVWpbW0GQR1XS
D-247MG NFHHVG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPMTWM2OD16Mj6wNlQ5KM7:TR?= NFW2W3RUSU6JRWK=
Becker M4HpNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPJT2hJUUN3ME24Nk4{PDhzIN88US=> NXP4O5lKW0GQR1XS
IST-MEL1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3qwVmlEPTB;OEKuN|Q5OiEQvF2= MoPJV2FPT0WU
MDA-MB-134-VI MleyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnThTWM2OD16Mj61PVk3KM7:TR?= M2Xi[3NCVkeHUh?=
NCI-H1092 MoK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTh2LkCxPVch|ryP NFLqO29USU6JRWK=
KINGS-1 NW\3XnZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvMNVBKSzVyPUi2MlE3OThizszN M4fLc3NCVkeHUh?=
HCC2218 MnyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTh4Lke5NVMh|ryP NWrXSFJ7W0GQR1XS
GI-ME-N MoDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTh5Lke2PVkh|ryP Mlz6V2FPT0WU
AM-38 NYCzPVZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\D[XBPUUN3ME24PE4{QTV|IN88US=> MnvLV2FPT0WU
KNS-42 NFPUW|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTkUolQUUN3ME24PU4yODF6IN88US=> NIPIfWxUSU6JRWK=
C8166 NIXiN3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPaPVZJUUN3ME24PU43OTJ3IN88US=> M4nsfnNCVkeHUh?=
Ramos-2G6-4C10 NHvXTVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXTZ285UUN3ME24PU45PzF7IN88US=> MkX5V2FPT0WU
CTB-1 NV\iSVFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVWyfVB4UUN3ME25NE43OzV5IN88US=> MVHTRW5ITVJ?
HCE-4 NHLleJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWL4V4czUUN3ME25NU4yOzN4IN88US=> MV3TRW5ITVJ?
NCI-H526 Moj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1v5emlEPTB;OUKuOFExOyEQvF2= M4PIXnNCVkeHUh?=
ECC4 Ml3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzxTnp5UUN3ME25OE4zPTV3IN88US=> M4HYXnNCVkeHUh?=
NCCIT MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{j3e2lEPTB;OUWuN|I6OiEQvF2= MUTTRW5ITVJ?
MZ7-mel NVu0TZRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTl3LkmwOEDPxE1? MUXTRW5ITVJ?
COLO-684 M2nZZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLSTWM2OD17Nj6yN|g2KM7:TR?= NFLHZlNUSU6JRWK=
SU-DHL-1 NWL1bHBnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTl4Lkm4OFIh|ryP NHS4eIdUSU6JRWK=
SF126 NF3KZ3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mly1TWM2OD17Nz61NlE4KM7:TR?= NYf2XXFtW0GQR1XS
NMC-G1 NWLYUGJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jrWWlEPTB;OUiuOFU2PCEQvF2= MUHTRW5ITVJ?
NB14 NVHwc3N1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTl6LkmyNFgh|ryP NVHJXXl[W0GQR1XS
VA-ES-BJ NVPlNnNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLITWM2OD17OT60NFU3KM7:TR?= NYP6bpdOW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Imatinib produces a different antitumor effect on three xenografted tumors derived from surgical samples of fresh human small cell lung cancers, with 80%, 40% and 78% growth inhibition of SCLC6, SCLC61 and SCLC108 tumors, respectively, and no significant inhibition of SCLC74 growth. [5] In high fat fed ApoE(-/-) mice, Imatinib significantly reduces the high fat-induced lipid staining area by 30%, 27% and 35% compared to high-fat diet untreated controls when dosed by gavage at 10, 20 and 40 mg/kg, respectively, and suppresses carotid artery lipid accumulation. [6]

Protocol

Kinase Assay:

[1]

+ Expand

PDGF receptor kinase activity:

PDGF receptor is immunoprecipitated from BALB/c 3T3 cell extracts with rabbit antiserum to the murine PDGF receptor for 2 hours on ice. Protein A-Sepharose beads are used to collect the antigen-antibody complexes. The immunoprecipitates are washed twice with TNET (50 mM Tris, pH 7.5, 140 mM NaCl, 5 mM EDTA, 1% Triton X-100), once with TNE (50 mM Tris, pH 7.5, 140 mM EDTA), and once with kinase buffer (20 mM Tris, pH 7.5,10 mM MgCl2). After stimulation with PDGF (50 ng/mL) for 10 minutes at 4 °C, different concentrations of drug are added to the reaction mixture. PDGF receptor kinase activity is determined by incubation with 10 μCi [7-33P]-ATP and l μM ATP for 10 minutes at 4 °C. Immune complexes are separated by SDS-PAGE on 7.5% gels.
Cell Research:

[3]

+ Expand
  • Cell lines: BON-1 cells and NCI-H727 cells
  • Concentrations: ~100 μM
  • Incubation Time: 48 hours
  • Method:

    BON-1 cells and NCI-H727 cells are seeded into flat-bottomed 96-well plates in triplicate and allowed to adhere overnight in 10% fetal bovine serum-supplemented DMEM or RPMI 1640 complete medium, respectively; the medium is then exchanged for serum-free medium (negative control) or serum-free medium containing serial dilutions of Imatinib. After 48 hours (control cultures do not reach confluence), the number of metabolically active cells is determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, and absorbance is measured in a Packard Spectra microplate reader at 540 nm. Growth inhibition is calculated using the following formula: inhibition rate = (1 − a / b) × 100%, where a and b are the absorbance values of the treated and control groups, respectively.


    (Only for Reference)
Animal Research:

[5]

+ Expand
  • Animal Models: SCLC6, SCLC61, SCLC 74 and SCLC108 small cell lung cancers are injected into Swiss mice (nu/nu, female).
  • Formulation: Imatinib is diluted in water.
  • Dosages: 70 or 100 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 4 mg/mL (8.1 mM)
Water slightly soluble or insoluble
Ethanol slightly soluble or insoluble
In vivo Add solvents individually and in order:

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 493.6
Formula

C29H31N7O

CAS No. 152459-95-5
Storage powder
in solvent
Synonyms CGP057148B, ST-1571

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00044304 Recruiting Hypereosinophilic Syndrome National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) August 22, 2002 Phase 2
NCT02644525 Not yet recruiting Loaisis National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) December 21, 2015 Phase 2
NCT03007147 Not yet recruiting B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|BCR-ABL1 Fusion Protein Expression|Minimal Residual Disease|Philadelphia Chromosome Positive|T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia Childrens Oncology Group|National Cancer Institute (NCI) July 2017 Phase 3
NCT03023046 Not yet recruiting Adult Acute Lymphoblastic Leukemia|Adult Lymphoblastic Lymphoma|CD20 Positive|Philadelphia Chromosome Positive University of Washington|National Cancer Institute (NCI) February 2017 Phase 2
NCT02538926 Not yet recruiting B Acute Lymphoblastic Leukemia|B Lymphoblastic Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent B Lymphoblastic Lymphoma|Recurrent T Lymphoblastic Leukemia/Lymphoma|Refractory B Lymphoblastic Lymphoma|Refractory T Lymphoblastic Lymphoma|T Acute Lymphoblastic Leukemia|T Lymphoblastic Lymphoma University of Washington|National Cancer Institute (NCI) January 2017 Phase 2
NCT02924714 Recruiting Gastrointestinal Stromal Tumor Oslo University Hospital January 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PDGFR Signaling Pathway Map

PDGFR Inhibitors with Unique Features

Related PDGFR Products

Tags: buy Imatinib (STI571) | Imatinib (STI571) supplier | purchase Imatinib (STI571) | Imatinib (STI571) cost | Imatinib (STI571) manufacturer | order Imatinib (STI571) | Imatinib (STI571) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID